<DOC>
	<DOCNO>NCT02833987</DOCNO>
	<brief_summary>The purpose study determine whether use direct oral anticoagulant ( DOACs ) associate increase risk major bleeding compare warfarin use , treatment venous thromboembolism ( VTE ) . The investigator carry separate population base cohort study use health administrative database eight jurisdiction Canada , UK US . Cohorts define initiation DOAC warfarin January 1 , 2009 , incident diagnosis VTE occur within 30 day prior date prescription DOAC warfarin . Follow-up continue hospitalization emergency department visit major bleed . The result separate site combine provide overall assessment risk major bleed DOAC user .</brief_summary>
	<brief_title>Direct Oral Anticoagulants Venous Thromboembolism</brief_title>
	<detailed_description>The objective study determine whether use direct oral anticoagulant ( DOACs ) associate increase risk major bleeding compare warfarin use , treatment venous thromboembolism ( VTE ) . A common-protocol approach use conduct retrospective cohort study use administrative health care data eight jurisdiction ( Canadian province Alberta , Manitoba , Nova Scotia , Ontario , Quebec , Saskatchewan , well United Kingdon ( UK ) Clinical Practice Research Datalink United States ( US ) Marketscan ) . Briefly , Canadian database include population-level data physician billing , diagnose procedure hospital discharge abstract , dispensation prescription drug . The data Nova Scotia , Ontario , Alberta restrict patient age 65 year old , prescription data available young patient . The CPRD clinical database representative UK population contains record patient see 680 general practitioner practice UK . In jurisdiction , investigator assemble study cohort include patient newly prescribe DOAC warfarin January 1 , 2009 ( early date data availability site ) October 2 , 2014 ( 180 day last date data availability site , early ) , incident diagnosis VTE within 30 day prior date prescription . The date study cohort entry define prescription ( CPRD ) dispensation ( site ) date newly prescribe DOAC warfarin . Patients study cohort follow date study cohort entry event ( define ) , censor due death departure database , 3 month cohort entry , end study period ( March 31 , 2015 ) , whichever occur first . Exposure DOAC define new prescription DOAC date cohort entry . Exposure warfarin define new prescription warfarin date cohort entry . The investigator use analysis analogous intention-to-treat approach . The primary outcome define hospitalization emergency department visit major bleed within 3 month cohort entry . The study cohort analyze use match cohort design , 5 warfarin user match DOAC user sex , age , cohort entry date , propensity score ( construct use multivariable logistic regression model estimate odds treat DOACs , adjust number pre-identified covariates account baseline difference time cohort entry ) . The hazard major bleed DOAC use vs. warfarin use estimate use Cox-proportional hazard regression model account potential correlation match pair . Meta-analyses site-specific result perform use fix random effect model ( accord result Chi-squared test heterogeneity ) . Sensitivity analysis conduct , define priori , assess robustness result . As secondary analysis , investigator : 1 ) ass risk all-cause mortality associate DOAC use compare warfarin use 3 month cohort entry ; 2 ) ass risk major bleed associate DOAC use compare warfarin use , accord chronic kidney disease status ; 3 ) determine ( descriptively ) proportion patient experience major bleed event major bleed type ; 4 ) stratify primary analysis age ( less 66 , 66-75 , 76-85 great 85 ) , sex , use anti-platelet medication 90 day period prior cohort entry .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients new prescription DOAC warfarin incident diagnosis VTE within 30 day prior date prescription Patients least 18 year age ( except Nova Scotia , Ontario , Alberta , patient least 66 year age ) Patients least 1 year history database Patients diagnosis VTE atrial fibrillation â‰¤335 day prior incident VTE diagnosis Patients receive prescription DOAC warfarin within 1 year prior date cohort entry Patients receive prescription DOAC warfarin date cohort entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Direct oral anticoagulant</keyword>
	<keyword>Safety</keyword>
	<keyword>Major bleed</keyword>
	<keyword>Adverse event</keyword>
</DOC>